BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11964734)

  • 1. Cellular and molecular pathogenesis of X-linked lymphoproliferative disease.
    Moretta A; Bottino C; Parolini S; Moretta L; Biassoni R; Notarangelo LD
    Curr Opin Allergy Clin Immunol; 2001 Dec; 1(6):513-7. PubMed ID: 11964734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells.
    Parolini S; Bottino C; Falco M; Augugliaro R; Giliani S; Franceschini R; Ochs HD; Wolf H; Bonnefoy JY; Biassoni R; Moretta L; Notarangelo LD; Moretta A
    J Exp Med; 2000 Aug; 192(3):337-46. PubMed ID: 10934222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. X-linked lymphoproliferative disease is caused by deficiency of a novel SH2 domain-containing signal transduction adaptor protein.
    Schuster V; Kreth HW
    Immunol Rev; 2000 Dec; 178():21-8. PubMed ID: 11213803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of the X-linked lymphoproliferative disease gene product SAP/SH2D1A with 2B4, a natural killer cell-activating molecule, is dependent on phosphoinositide 3-kinase.
    Aoukaty A; Tan R
    J Biol Chem; 2002 Apr; 277(15):13331-7. PubMed ID: 11815622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The abnormal gene in X-linked lymphoproliferative syndrome.
    Sullivan JL
    Curr Opin Immunol; 1999 Aug; 11(4):431-4. PubMed ID: 10448142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A spectrum of mutations in SH2D1A that causes X-linked lymphoproliferative disease and other Epstein-Barr virus-associated illnesses.
    Sumegi J; Seemayer TA; Huang D; Davis JR; Morra M; Gross TG; Yin L; Romco G; Klein E; Terhorst C; Lanyi A
    Leuk Lymphoma; 2002 Jun; 43(6):1189-201. PubMed ID: 12152986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for SH2D1A mutations in X-linked lymphoproliferative disease.
    Lappalainen I; Giliani S; Franceschini R; Bonnefoy JY; Duckett C; Notarangelo LD; Vihinen M
    Biochem Biophys Res Commun; 2000 Mar; 269(1):124-30. PubMed ID: 10694488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The X-linked lymphoproliferative syndrome gene product SH2D1A associates with p62dok (Dok1) and activates NF-kappa B.
    Sylla BS; Murphy K; Cahir-McFarland E; Lane WS; Mosialos G; Kieff E
    Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7470-5. PubMed ID: 10852966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease.
    Sumegi J; Huang D; Lanyi A; Davis JD; Seemayer TA; Maeda A; Klein G; Seri M; Wakiguchi H; Purtilo DT; Gross TG
    Blood; 2000 Nov; 96(9):3118-25. PubMed ID: 11049992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients.
    Yin L; Ferrand V; Lavoué MF; Hayoz D; Philippe N; Souillet G; Seri M; Giacchino R; Castagnola E; Hodgson S; Sylla BS; Romeo G
    Hum Genet; 1999 Nov; 105(5):501-5. PubMed ID: 10598819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients.
    Morra M; Simarro-Grande M; Martin M; Chen AS; Lanyi A; Silander O; Calpe S; Davis J; Pawson T; Eck MJ; Sumegi J; Engel P; Li SC; Terhorst C
    J Biol Chem; 2001 Sep; 276(39):36809-16. PubMed ID: 11477068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene.
    Coffey AJ; Brooksbank RA; Brandau O; Oohashi T; Howell GR; Bye JM; Cahn AP; Durham J; Heath P; Wray P; Pavitt R; Wilkinson J; Leversha M; Huckle E; Shaw-Smith CJ; Dunham A; Rhodes S; Schuster V; Porta G; Yin L; Serafini P; Sylla B; Zollo M; Franco B; Bolino A; Seri M; Lanyi A; Davis JR; Webster D; Harris A; Lenoir G; de St Basile G; Jones A; Behloradsky BH; Achatz H; Murken J; Fassler R; Sumegi J; Romeo G; Vaudin M; Ross MT; Meindl A; Bentley DR
    Nat Genet; 1998 Oct; 20(2):129-35. PubMed ID: 9771704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The gene defective in X-linked lymphoproliferative disease controls T cell dependent immune surveillance against Epstein-Barr virus.
    Howie D; Sayos J; Terhorst C; Morra M
    Curr Opin Immunol; 2000 Aug; 12(4):474-8. PubMed ID: 10899030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene.
    Arico M; Imashuku S; Clementi R; Hibi S; Teramura T; Danesino C; Haber DA; Nichols KE
    Blood; 2001 Feb; 97(4):1131-3. PubMed ID: 11159547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation-dependent T cell expression of the X-linked lymphoproliferative disease gene product SLAM-associated protein and its assessment for patient detection.
    Shinozaki K; Kanegane H; Matsukura H; Sumazaki R; Tsuchida M; Makita M; Kimoto Y; Kanai R; Tsumura K; Kondoh T; Moriuchi H; Miyawaki T
    Int Immunol; 2002 Oct; 14(10):1215-23. PubMed ID: 12356686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defective NK cell activation in X-linked lymphoproliferative disease.
    Benoit L; Wang X; Pabst HF; Dutz J; Tan R
    J Immunol; 2000 Oct; 165(7):3549-53. PubMed ID: 11034354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [X-linked lymphoproliferative syndrome, EBV virus infection and defects in cytotoxicity lymphocyte regulation].
    Malbrán A; Belmonte L; Ruibal-Ares B; Baré P; Bracco MM
    Medicina (B Aires); 2003; 63(1):70-6. PubMed ID: 12673966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. X-linked lymphoproliferative disease: a progressive immunodeficiency.
    Morra M; Howie D; Grande MS; Sayos J; Wang N; Wu C; Engel P; Terhorst C
    Annu Rev Immunol; 2001; 19():657-82. PubMed ID: 11244050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis and diagnosis of X-linked lymphoproliferative disease.
    Gilmour KC; Gaspar HB
    Expert Rev Mol Diagn; 2003 Sep; 3(5):549-61. PubMed ID: 14510176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct interactions of the X-linked lymphoproliferative syndrome gene product SAP with cytoplasmic domains of members of the CD2 receptor family.
    Lewis J; Eiben LJ; Nelson DL; Cohen JI; Nichols KE; Ochs HD; Notarangelo LD; Duckett CS
    Clin Immunol; 2001 Jul; 100(1):15-23. PubMed ID: 11414741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.